Caxton Corp
- SEC CIK
- 0001388551
- Latest filing
- Aug 13, 2026
Holdings in Q1 2024
Holdings as of Mar 31, 2024, filed May 15, 2024. Long positions only; changes compare share counts with Q4 2023.
- Positions
- 11
- −1 vs. Q4 2023
- Portfolio value
- $17.6M
- −$972.8K (−5.3%) vs. Q4 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ACETAdicet Bio, Inc. | COM | 17,488 | $41.1K | 0.2% | +17,488 | New | History |
| CMPXCompass Therapeutics, Inc. | COM | 43,465 | $86.1K | 0.5% | 00.0% | Unchanged | History |
| LXEOLexeo Therapeutics, Inc. | COM | 10,319 | $161.8K | 0.9% | 00.0% | Unchanged | History |
| ABVXAbivax S.A. | SPONSORED ADS | 15,808 | $226.1K | 1.3% | −935−5.6% | Reduced | History |
| DFTXDefinium Therapeutics, Inc. | Stock | 29,065 | $273.2K | 1.6% | +29,065 | New | History |
| MTEMMolecular Templates, Inc. | COM NEW | 136,866 | $306.6K | 1.7% | 00.0% | Unchanged | History |
| KYTXKyverna Therapeutics, Inc. | COM | 15,846 | $393.6K | 2.2% | +15,846 | New | History |
| BRK.BBerkshire Hathaway Inc | Stock | 1,019 | $428.3K | 2.4% | −16−1.5% | Reduced | History |
| SPYSPDR S&P 500 ETF Trust | ETF | 1,856 | $971.0K | 5.5% | +534+40.4% | Added | History |
| RZLTRezolute, Inc. | COM NEW | 1,318,967 | $3.36M | 19.2% | 00.0% | Unchanged | History |
| XERSXeris Biopharma Holdings, Inc. | COM | 5,113,348 | $11.3M | 64.4% | −528,572−9.4% | Reduced | History |
Sold out since Q4 2023 (4)
Positions held at the end of Q4 2023 that are gone from this filing.
| Security | Class | Shares in Q4 2023 | Value in Q4 2023 | % of portfolio in Q4 2023 | History |
|---|---|---|---|---|---|
| SVRASavara Inc | COM | 353,441 | $1.66M | 9.0% | History |
| APGEApogee Therapeutics, Inc. | COM | 7,353 | $205.4K | 1.1% | History |
| HARPHarpoon Therapeutics, Inc. | COM NEW | 13,176 | $129.3K | 0.7% | History |
| ALLKAllakos Inc. | COM | 24,710 | $67.5K | 0.4% | History |